First Quarter 2024 Financial Results May 2, 2024 1 © 2024 Alnylam Pharmaceuticals, Inc. Agenda Welcome • Christine Lindenboom ...

Alnylam Pharmaceuticals (ALNY) reported $494.33 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 54.8%. EPS of -$0.16 for the same period compares to -$1.40 a year ago. The reported revenue represents a surprise of +17.39% over the Zacks Consensus Estimate of $421.1 million. With the consensus EPS estimate being -$0.75, the EPS surprise was +78.67%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they c ...

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 78.67%. A quarter ago, it was expected that this RNA interference drug developer would post a loss of $1.20 per share when it actually produced a loss of $1.10, delivering a surprise of 8.33%. Over the last four q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number 001-36407 ___________________ ...

Analysts on Wall Street project that Alnylam Pharmaceuticals (ALNY) will announce quarterly loss of $0.75 per share in its forthcoming report, representing an increase of 46.4% year over year. Revenues are projected to reach $421.1 million, increasing 31.9% from the same quarter last year. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Alnylam Pharmaceuticals (ALNY) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

公司表现 - Alnylam Pharmaceuticals, Inc. (ALNY) 是医疗 - 生物医学和遗传学领域的一个有趣选择[1] - Alnylam Pharmaceuticals 近期看起来也表现不错，过去一个月内，盈利预期修订活动稳健[3] 行业趋势 - 医疗 - 生物医学和遗传学领域目前处于良好位置，Zacks Industry Rank 为73，显示行业整体表现强劲[2] 公司评级 - 公司当前持有 Zacks Rank 3 (Hold)，也是一个积极信号[4]

项目推出 - Alnylam Pharmaceuticals宣布推出Family Health History Road Trip项目，旨在鼓励家庭成员之间就健康史展开对话[1] 疾病特征 - hATTR淀粉样变性病是一种由遗传变异引起的快速进展性疾病，常见症状包括手腕管综合征、手脚麻木、无力、呼吸困难等，症状类似于其他常见疾病，可能导致误诊或延误诊断[2] 诊断重要性 - 早期诊断对于hATTR淀粉样变性病至关重要，延迟诊断会延迟疾病管理，因此家庭成员之间进行健康史对话至关重要[3]

临床试验结果 - Alnylam Pharmaceuticals (ALNY)和合作伙伴Roche (RHHBY)宣布了他们的RNAi治疗药物zilebesiran在高血压成人中的积极结果[1] - KARDIA-2研究招募了672名轻度至中度高血压的成人，他们被随机分配接受600毫克剂量的zilebesiran或安慰剂，同时服用三种批准的高血压药物之一[2] - 接受zilebesiran治疗的研究参与者在三个月时达到了研究的主要终点，即收缩压（SBP）在24小时动态血压监测（ABPM）中显著降低[3] - zilebesiran在添加到标准一线抗高血压药物时表现出令人鼓舞的安全性和耐受性[4] 合作协议 - Roche向Alnylam支付了3.1亿美元的前期款项，并有权获得高达28亿美元的里程碑付款，以及在美国的利润和损失的平等份额以及在国外净销售额的版税[10]

As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YO ...